OPKO Health, Inc. Participates in Latest Round of Financing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OPKO Health, Inc. Participates in Latest Round of Financing for MabVax Therapeutics

SAN DIEGO, CA --(Marketwired - October 08, 2015) - MabVax Therapeutics Holdings, Inc. ( OTCQB : MBVX ) ("MabVax" or "Company"), a clinical-stage cancer immunotherapy company, previously announced that it has closed its public offering of 2,500,000 shares of its common stock and warrants to purchase up to 1,250,000 shares of its common stock. OPKO Health ( NYSE : OPK ) participated in the financing and was one of the largest investors in the round. This is the second investment made by OPKO Health, Inc. this year in MabVax.

Commenting on the continued investment in MabVax, Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc., stated, "This supplemental financing will provide MabVax with additional funds to advance the Company's lead antibody program into early clinical trials next year potentially reaching key milestones by mid-year next year.

David Hansen, President and CEO of MabVax said, "We are proud to have the continued support of OPKO Health. MabVax intends to use the proceeds from the financing to file two INDs in 2015 and initiate two Phase 1 trials for its HuMab 5B1 antibody program in early 2016." Currently the HuMab 5B1 antibody is being developed as both a diagnostic and therapeutic product targeting metastatic pancreatic and colon cancer.

About HuMab 5B:

In preclinical research MabVax's HuMab 5B1 antibody has demonstrated high specificity, affinity and lack of cross-reactivity with closely related antigens. The antibody has also shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancer. When combined with a radio-label as a novel PET imaging agent, 89 Zr-HuMab 5B1 has demonstrated high image resolution of tumors in established xenograft animal models, making it attractive as a companion diagnostic for the therapeutic product.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MabVax:

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of vaccine and antibody-based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax also has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof-of-concept Phase II multicenter clinical trials, and a vaccine targeting neuroblastoma that will be ready for a Phase II clinical trial in 2016. Additional information is available at www.mabvax.com .

Forward Looking Statements

This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's development pipeline. We have no assurance that all of the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov . The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact: Jody Cain Senior Vice President LHA 310-691-7100 jcain@LHAI.com Robert B. Prag President The Del Mar Consulting Group, Inc. 858-794-9500 bprag@delmarconsulting.com Scott Wilfong President Alex Partners, LLC 425-242-0891 scott@alexpartnersllc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 16

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Motorsport Games Achieves Significant Growth in Q3 Results

Updated Category News Views 182

Motorsport Games Shows Promising Financial Trends Motorsport Games Inc. (NASDAQ: MSGM) recently shared its financial outcomes for the third quarter, reflecting remarkable growth. The company, a key player in the racing game industry, recorded significant advancements, particularly highlighted by their flagship title, Le Mans Ultimate. For Q3 2025, Motorsport Games...

Continue Reading
AI Giants Converge in Singapore for SuperAI 2026

Updated Category News Views 52

SuperAI Singapore 2026: A Global Gathering Singapore's Marina Bay Sands is buzzing, folks. With 10,000 people crammed into Asia's largest AI event, SuperAI Singapore 2026 is offering up a melting pot of tech brains from 150 countries. It's sold out like your favorite band’s farewell tour—things kicking off with a big bang. A Melting Pot of Innovation You’ve got...

Continue Reading
Investors' Sentiment Towards Terreno Realty Corp Revealed

Updated Category News Views 128

Understanding Investor Sentiment for Terreno Realty Corp Terreno Realty's short interest has notably surged, reflecting a growing sentiment among investors. Currently, 11.02% increase in short interest reveals that now approximately 6.22 million shares are sold short, making it 10.78% of the float. Observing the trading volume suggests that it would take traders roughly...

Continue Reading
Gilead Sciences Targets Growth Amid Oncology Challenges and Opportunities

Updated Category News Views 208

Gilead Sciences faced significant challenges back in 2024 as its oncology ambitions faltered, all while the company leaned heavily on its HIV stronghold. The stock stumbled, reflecting broader market jitters about its future growth potential. You see, Gilead had been riding high on Biktarvy, a blockbuster that held nearly 49% of the U.S. HIV treatment market. Analysts...

Continue Reading
Captify Launches Innovative Election War Room Insights 2024

Updated Category News Views 124

Captify Launches the Election War Room for the 2024 Elections Captify, a leader in real-time audience analytics powered by Search Intelligence, has introduced the Captify Election War Room—a weekly data report that spotlights what people are searching for during the 2024 U.S. election cycle. As the race intensifies, brands and campaign teams want a clearer view of how...

Continue Reading